

For professional *in vitro* diagnostic use only.

INTENDED USE

The Syphilis Rapid Test Device (Whole blood/Serum/Plasma) is an *in vitro* diagnostic rapid immunochromatographic assay for the qualitative detection of antibodies to *Treponema pallidum* in human whole blood, serum and plasma specimens. The product may be used as an aid in the diagnosis of syphilis. A reactive result should be confirmed by other supplemental assay(s).

INTRODUCTION

Syphilis is a sexually transmitted infection caused by the bacterium *Treponema pallidum* subspecies *pallidum*¹. The signs and symptoms of syphilis vary depending in which of the four stages it presents (primary, secondary, latent, and tertiary). In latent syphilis, which can last for years, there are few or no symptoms².

Syphilis is transmitted primarily by sexual contact or during pregnancy from a mother to her fetus; the spirochete is able to pass through intact mucous membranes or compromised skin³. Syphilis is a notifiable disease in many countries, including Canada⁴ the European Union⁵, and the United States⁶. Approximately 30% to 60% of those exposed to primary or secondary syphilis will get the disease⁷. In 2015, about 45.4 million people were infected with syphilis⁸, with 6 million new cases⁹. Untreated, it has a mortality of 8% to 58%, with a greater death rate in males³. With early treatment, few complications result¹⁰.

Syphilis is difficult to diagnose clinically early in its presentation. Confirmation is either via blood tests or direct visual inspection using microscopy. Blood tests are more commonly used, as they are easier to perform³. Because of the possibility of false positives with nontreponemal tests, confirmation is required with a treponemal test, such as treponemal pallidum particle agglutination (TPHA) or fluorescent treponemal antibody absorption test (FTA-Abs)³. Treponemal antibody tests usually become positive 2-5 weeks after the initial infection¹⁰.

PRINCIPLE

The Syphilis Rapid Test Device detects antibodies to *T. pallidum* (TP) through visual interpretation of color development on the internal strip. Recombinant antigens representing epitopes of TP (15kD, 17kD, 47kD) are immobilized on the test region of the membrane.

During testing, the specimen reacts with recombinant TP-specific antigens conjugated to colored particles and precoated onto the sample pad of the test. The mixture then migrates through the membrane by capillary action and interacts with reagents on the membrane. If there are sufficient antibodies to TP in the specimen, a colored band will form at the test region of the membrane.

The presence of this colored band indicates a positive result, while its absence indicates a negative result. The appearance of a colored band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking has occurred.

MATERIALS

Materials Provided

- Test devices
- Buffer
- Droppers
- Package insert

Materials Required But Not Provided

- Specimen collection equipment and container
- Timer
- Centrifuge

WARNINGS AND PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Read these instructions carefully before performing the test.
- Do not use the test beyond the expiration date.
- Do not use the test if the packaging is damaged.
- Do not reuse tests.
- Apply standard biosafety precautions when handling and disposing of potentially infectious materials.
- Handle all specimens as potentially infectious.
- Wear protective clothing such as gloves, laboratory coats, and eye protection when specimens are being assayed.
- The test device and accessory should be disposed in a proper biohazard waste container after testing.
- Do not eat, drink or smoke in the area where the specimens and kits are handled.
- Avoid splashes and clean up spills immediately with appropriate disinfectant.
- The buffer contains 0.02% sodium azide as a preservative which may be toxic if ingested. When disposed of through a sink, flush with large quantities of water.
- Avoid cross-contamination of specimens by using a new specimen collection container for each specimen obtained.
- Humidity and temperature can adversely affect results.
- Do not use any other specimen than those specified. For venous whole blood and plasma, EDTA, sodium citrate, sodium heparin or potassium oxalate can be used as anticoagulant.
- Used testing materials should be discarded in accordance with local regulations.

STORAGE AND STABILITY

- The kit should be stored at 2-30°C until the expiry date printed on the sealed pouch.
- The test must remain in the sealed pouch until use.
- Do not freeze the kit.
- Protect the kit from humidity.
- Care should be taken to protect the components of the kit from contamination. Do not use the test if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

SPECIMEN COLLECTION AND PREPARATION

- The Syphilis Rapid Test Device (Whole Blood/Serum/Plasma) is intended for use with human whole blood, serum or plasma specimens only.
- Collect specimens according to safe phlebotomy procedure.
- Only clear, non-hemolyzed specimens are recommended for use with this test. Serum or plasma should be separated as soon as possible to avoid hemolysis.
- Perform testing immediately after specimen collection. Do not leave specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 7 days. For long term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 3 days of collection. Do not freeze whole blood specimens.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Multiple freeze/ thaw cycles should be avoided.
- If specimens are to be shipped, pack them in compliance with all applicable regulations for transportation of etiological agents.

- Icteric, lipemic, hemolysed, heat treated and contaminated sera may cause erroneous results.

TEST PROCEDURE

Bring the test device, buffer and specimen to room temperature (15-30°C) prior to testing.

1. Remove the test device from its sealed pouch and use it as soon as possible. For best results, the assay should be performed within one hour.
2. Place the test device on a clean, level surface. Label with specimen ID.

For **venous whole blood** specimens:

Hold the dropper vertically and **transfer 2 drops of whole blood** (approximately 50 µL) to the sample well (S) of the test device, then **add 1 drop of buffer** (approximately 40 µL) and start the timer.

For **fingerstick whole blood** specimens:


Dispense 2 drops of fingerstick whole blood onto the sample well (S) of the test device, then **add 1 drop of buffer** (approximately 40 µL) and start the timer.

For **serum or plasma** specimens:

Hold the dropper vertically and transfer **3 drops of serum or plasma** (approximately 75 µL) to the sample well (S) of the test device, and start the timer.

Avoid trapping air bubbles in the specimen well (S), and do not add any solution to the result area.

3. Wait for the colored band to appear. **Read results at 10 minutes.**



INTERPRETATION OF RESULTS

POSITIVE: Two colored lines appear. One line should always appear in the control region (C), and another line appears in the test region (T).

NEGATIVE: Only one colored line appears in the control region (C). No apparent colored line appears in the test region (T).

INVALID: No line appears in the control region (C). Results from any test which has not produced a control line at the specified reading time must be discarded. Please review the test procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

NOTE:

1. The intensity of color in the test region (T) may vary depending on the

concentration of analytes present in the specimen. However, any shade of color in the test region should be considered positive. Note that this is a qualitative test only, and the concentration of analytes in the specimen cannot be determined.

2. Insufficient specimen volume, incorrect operating procedure or expired tests are the most likely reasons for control line failure.

QUALITY CONTROL

- An internal procedural control is included in the test. A colored line appearing in the control region (C) is considered an internal positive procedural control, confirming sufficient specimen volume and correct procedural technique. The control line does not control for the addition of adequate volume of specimen.
- External quality controls are not supplied with this kit. It is recommended that quality controls be tested as a good laboratory practice.

LIMITATIONS

- The Syphilis Rapid Test Device (Whole Blood/Serum/Plasma) is for professional *in vitro* diagnostic use only, and should be used for the qualitative detection of antibodies to *T. pallidum* in human whole blood, serum or plasma.
- The Syphilis Rapid Test Device (Whole Blood/Serum/Plasma) will only indicate the presence of antibodies to *T. pallidum* in the specimen and should not be used as the sole criteria for the diagnosis of Syphilis.
- For confirmation of test results, specimens should undergo further testing using different assays, such as rapid diagnostic tests, EIA, in accordance with a validated syphilis testing algorithm.
- As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
- False reactive results may arise due to damage to test components by heat or humidity, when other test kit components (e.g. buffer or droppers) are substituted between test kits.
- False non-reactive results may arise when titers of antibodies to *T. pallidum* are very low, titers of antibodies to *T. pallidum* are very high (hook effect), insufficient specimen volume added, excess of buffer added, damage to test components by heat or humidity.

PERFORMANCE CHARACTERISTICS

Analytical Sensitivity

The analytical sensitivity of the Syphilis Rapid Test Device has been verified with the WHO International Standard for 1st IS for human syphilitic plasma IgG (NIBSC code 05/122) and IgG+IgM (NIBSC code 05/132). The analytical sensitivity of Syphilis Rapid Test Device is 5 mIU/mL for 05/122, and 10 mIU/mL for 05/132.

Clinical Evaluation

Clinical Evaluation on Serum and Plasma Specimens

The performances of the Syphilis Rapid Test Device (Whole Blood/Serum/Plasma) have been established in comparison with TPHA. A total of 593 serum and plasma samples, collected from independent subjects, were tested in the study. The testing results were summarized in the table below:

Table 1: Clinical Evaluation on Serum and Plasma Specimens

Relative Sensitivity: 99.6% (97.7%-99.9%)* Relative Specificity: 99.1% (97.5%-99.7%)*	Syphilis Rapid Test (serum/plasma)			Total
		+	-	
TPHA	+	246	1	247
	-			

Overall Agreement: 99.3% (98.3%-99.7%)* *95% Confidence Interval	-	3	343	346
		249	344	593

Clinical Evaluation on Venous Whole Blood Specimens

For venous whole blood specimen validation, 250 clinically diagnosed Syphilis-positive venous whole blood specimens (EDTA as anticoagulant), and 100 negative venous whole blood specimens (EDTA as anticoagulant), collected from independent subjects, were included in the study.

Venous whole blood specimens were collected in anticoagulant tubes with EDTA, and tested by the Syphilis Rapid Test Device (Whole Blood/Serum/Plasma) within 3 days after specimen collection. The venous whole blood specimens were centrifuged to collect plasma specimens for TPHA test. The testing result was summarized in the table below:

Table 2: Clinical Evaluation on Venous Whole Blood Specimens

Relative Sensitivity: >99% (98.5%-100%)* Relative Specificity: >99% (96.3 %-100%)* Overall Agreement: >99% (98.9%-100%)* (*95% Confidence Interval)	Syphilis Rapid Test (venous whole blood)			Total
		+	-	
TPHA	+	250	0	250
	-	0	100	100
		250	100	350

Clinical Evaluation on Fingerstick Whole Blood Specimens

For fingerstick whole blood specimen validation, 50 clinically diagnosed Syphilis-positive fingerstick whole blood specimens, and 50 Syphilis-negative fingerstick whole blood specimens, collected from independent subjects, were included in the study. Meanwhile, serum specimens were collected from the 100 donors for TPHA test. Fingerstick whole blood specimens were tested immediately on the Syphilis Rapid Test Device (Whole Blood/Serum/Plasma). Serum specimens from these 100 donors were tested by TPHA for comparison.

Table 3: Clinical Evaluation on Fingerstick Whole Blood Specimens

Relative Sensitivity: >99% (92.9%-100%)* Relative Specificity: >99% (92.9 %-100%)* Overall Agreement: >99% (96.3%-100%)* (*95% Confidence Interval)	Syphilis Rapid Test (fingerstick whole blood)			Total
		+	-	
TPHA	+	50	0	50
	-	0	50	50
		50	50	100

Specimen Type Equivalency

Four specimen types (serum, plasma, venous whole blood, fingerstick whole blood) were collected from individuals known to be positive for syphilis (n=50) and from individuals negative for syphilis (n=50). Each specimen was confirmed by TPHA. The result demonstrated 100% agreement between specimen types and with expected results in known positive Syphilis specimens and in negative Syphilis specimens.

Anticoagulant Type Equivalency

To evaluate the equivalency of three anticoagulant types (EDTA, sodium heparin, and sodium citrate) on the assay performance, 25 Syphilis-positive venous whole blood specimens, 25 Syphilis-positive plasma specimens, 25 Syphilis-negative

venous whole blood specimens and 25 Syphilis-negative plasma specimens for each anticoagulant type. The results demonstrated that sodium heparin and sodium citrate are equivalent to EDTA for the detection of Syphilis antibody.

Interference Substances

The assay performance of Syphilis Rapid Test Device was not affected by the following analytes at listed amounts:

Analytes	Amount	Analytes	Amount
Acetaminophen	20 mg/dL	γ globulin	60 g/L
Caffeine	20 mg/dL	HAMA	780.73 IU/mL
Aspirin	20 mg/dL	Metronidazole	701 μmol/L
Gentistic acid	20 mg/dL	Quinine	148 μmol/L
Oxalic acid	60 mg/dL	Rifampin	78.1 μmol/L
Creatine	200 mg/dL	Aspirin	4.34 mmol/L
Methanol	10%	Paracetamol	199 μmol/L
Ascorbic acid	2,000 mg/dL	Ibuprofen	2,425 μmol/L
Albumin	2,000 mg/dL	Ethanol	86.8 mmol/L
Hemoglobin	1,000 μg/dL	EDTA	3.4 μmol/L
Bilirubin	1,000 mg/dL	Heparin	3,000 U/L
Rheumatoid factor	1,035 IU/mL	Citrate	4%
Acetoacetic Acid	2,000 mg/dL		

Pregnancy Specimens Testing

To evaluate whether pregnancy would affect the assay performance of the device, specimens from 100 pregnant women including 30 venous whole blood specimen, 30 plasma specimens, and 40 serum specimens were tested. The results showed that the assay performance of the Syphilis Rapid Test Device was not affected by pregnancy specimens.

Cross Reactivity

The assay performance of the Syphilis Rapid Test Device was not affected by the following infections: HIV, HBV, HCV, HAV, Tuberculosis, *Toxoplasma gondii*, Rubella, CMV, HSV-1, HSV-2, Typhoid, Influenza A, Influenza B, and Dengue.

LITERATURE REFERENCES

- "Syphilis". CDC. June 4, 2015. Retrieved3 February 2016.
- "Syphilis - CDC Fact Sheet (Detailed)".CDC. November 2, 2015. Retrieved3 February 2016.
- Kent ME, Romanelli F (February 2008). "Reexamining syphilis: an update on epidemiology, clinical manifestations, and management". *Annals of Pharmacotherapy*. 42(2): 226–36. PMID 18212261.doi:10.1345/aph.1K086.
- "National Notifiable Diseases". Public Health Agency of Canada. 5 April 2005. Retrieved 2 August 2011.
- Viñals-Iglesias, H; Chimenos-Küstner, E (1 September 2009). "The reappearance of a forgotten disease in the oral cavity: syphilis". *Medicina oral, patologia oral y cirugía bucal*. 14 (9): e416–20.PMID 19415060.
- "Table 6.5. Infectious Diseases Designated as Notifiable at the National Level-United States, 2009 [a]". Red Book. Retrieved 2 August 2011.
- Bhatti MT (2007). "Optic neuropathy from viruses and spirochetes". *Int Ophthalmol Clin*. 47 (4): 37–66, ix. PMID 18049280.doi:10.1097/IIO.0b013e318157202d.
- GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic

analysis for the Global Burden of Disease Study 2015.". Lancet. 388 (10053): 1545–1602.PMID 27733282.

9. Newman, L; Rowley, J; Vander Hoorn, S; Wijesooriya, NS; Unemo, M; Low, N; Stevens, G; Gottlieb, S; Kiarie, J; Temmerman, M (2015). "Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting.". PLOS ONE. 10 (12): e0143304.PMC 4672879 PMID 26646541.doi:10.1371/journal.pone.0143304.

10.Eccleston, K; Collins, L; Higgins, SP (March 2008). "Primary syphilis". International journal of STD & AIDS. 19(3): 145–51. PMID 18397550. doi:10.1258/ijsa.2007.007258.

GLOSSARY OF SYMBOLS			
ρ	Catalog number	θ	Temperature limitation
ι	Consult instructions for use	Δ	Batch code
I	In vitro diagnostic medical device	ε	Use by
μ	Manufacturer	Τ	Contains sufficient for <n> tests
σ	Do not reuse	Λ	Authorized representative in the European Community
Υ	CE marking according to IVD Medical Devices Directive 98/79/EC		

Dia Sure

μ

Assure Tech. (Hangzhou) Co., Ltd.
Building 4, No. 1418-50, Moganshan Road,
Gongshu District, Hangzhou,
310011Zhejiang, P.R.China
contact@diareagent.com

Y

A

Lotus NL B.V.
KoninginJulianaplein 10, le Verd,
2595AA,The Hague,Netherlands
peter@lotusnl.com